Strides Shasun to launch Ranitidine 75mg OTC Tablets

08 Mar 2018 Evaluate

Strides Shasun is planning to launch Ranitidine Tablets USP, 75 mg (OTC) for the US markets. The new launch will further strengthen Strides’ Ranitidine portfolio that now includes Ranitidine Tablets 150 mg and 300 mg in the Rx space and Ranitidine Tablets 75 mg and 150 mg in the OTC space. The company is already a key player with 32% share of the US Rx market for Ranitidine. According to IRI data, the US OTC market for Ranitidine Tablets, which is the generic form of the popular brand Zantac, is approximately $200 million.

This is the second product approval from company’s 50:50 JV with Vivimed Labs. The product will be backward integrated and will be manufactured at the JV’s Oral dosage facility in Chennai. Strides will have exclusive marketing rights for the product in the US. The product will be launched immediately.

The company has 82 cumulative ANDA filings with USFDA (including its JV with Vivimed) of which 51 ANDAs have been approved as of date and 31 are pending approval.

Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.


Strides Pharma Scien Share Price

878.65 -7.00 (-0.79%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×